Food & function
Cure8 research brief
Why This Matters
The study suggests a new probiotic strategy that targets both microbial H2S production and host detoxification pathways — processes implicated in some IBD-related dysbiosis — which could inform future microbiome-directed therapies.
Who Should Pay Attention
Researchers, clinicians focused on microbiome therapies, and patients interested in emerging probiotic research.
Study Snapshot
Story typeResearch paper
Evidence typeResearch paper
Source depthJournal abstract
What To Know
This lab-based study (abstract-level) reports that a probiotic strain, Lactobacillus brevis ZFM820, reduced Desulfovibrio-driven colitis in experimental models by two linked mechanisms: the strain secretes phenyllactic acid (PLA) which inhibits Desulfovibrio’s sulfate-reduction (lowering H2S production), and viable ZFM820 promotes expansion of Lacrimispora
and butyrate production, which in turn upregulated host sulfide-detoxifying enzymes (SQR and TST) to clear luminal H2S and help restore barrier and mitochondrial function.
The report emphasizes that neither PLA nor butyrate alone reproduced the protective effects — live ZFM820 integrating both ecological and metabolic actions was required.
The findings are presented as a preclinical/experimental demonstration of a targeted ecological strategy to rebalance intestinal sulfur metabolism and counteract a Desulfovibrio-associated pathobiont effect.
Keep In Mind
Preclinical/basic-science findings reported in an abstract; not evidence of clinical benefit. Further animal and human studies are needed before clinical use.
Source Details
Review the original publication for the complete reporting, methods, and context.
Research paper
Evidence type derived from source or registry metadata.
PublicationFood & function
AuthorsLi Y, Yang C, Li L +6 more
Study typeJournal article
Indexed viaEurope PMC
Source typeResearch paper
PublishedAug 14, 2026, 12:00 AM
Content availableJournal abstract
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Lactobacillus brevis Desulfovibrio ZFM820 modulates intestinal ecological sulfur homeostasis to alleviate-driven colitis.
The study suggests a new microbiome-based strategy that targets toxic hydrogen sulfide production and boosts host detoxification — a mechanism potentially relevant to some forms of IBD driven by sulfur-metabolizing...
Gut commensal Lachnospira eligens alleviates ulcerative colitis by mediating isodeoxycholic acid via the STAT3/NF-κB signaling pathway
The study identifies a specific gut microbe and a bile-acid metabolite that reduced inflammation in a mouse colitis model and implicates STAT3/NF-κB pathways — a potential new avenue for microbiome-based therapeutics for...
Expansion resistance against genotoxic E. coli: protective effects of Bifidobacterium pseudolongum in DSS-induced colitis in mice.
The work suggests that specific gut bacteria or their metabolic products (acetate, putrescine) can limit harmful E. coli expansion and reduce inflammation in a mouse model of colitis, which could inform future probiotic...